What to Know About the Finalized COVID-19 Study Blocked by CDC
What to know about COVID 19 study – After months of delay, a critical analysis of the 2025-26 COVID-19 vaccine’s effectiveness was finally released Tuesday. The research, which had been withheld by the Centers for Disease Control and Prevention (CDC) from its weekly report, has now been published in the peer-reviewed journal *JAMA Network Open*. The findings highlight the vaccine’s role in reducing severe outcomes, offering hope for public health strategies as the pandemic evolves.
Study Focuses on Adult Population Without Immune Weakness
The study, led by researchers from the CDC and several U.S. states—including California, Colorado, Georgia, Indiana, Maryland, Minnesota, New York, Oregon, Texas, and Utah—examined the vaccine’s impact on adults aged 18 and older who do not have compromised immune systems. It analyzed data collected during the fall and winter of 2025, a period marked by rising cases and increased pressure on healthcare systems. The researchers found that the updated vaccines significantly cut the risk of hospitalization by 55% and emergency department or urgent care visits by 50% among vaccinated individuals compared to those who received no shots.
Dr. Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, expressed surprise at the CDC’s decision to block the study. “The head scratcher is why CDC would block [the study],” he told ABC News. “If anything, what they should be doing in order to encourage people to get vaccinated is to be putting up all of the papers showing effectiveness of vaccinations so people could follow it in time, and so to try to obscure the results or block it goes against public health.”
Methodology Sparks Debate Among Scientists
The study employed a test-negative design, a method used to evaluate vaccine effectiveness in real-world settings. This approach compares individuals who seek medical care for symptoms and test positive for a disease with those who test negative, allowing researchers to assess how often vaccinated people require treatment compared to unvaccinated ones. Despite its widespread use in prior research, the CDC’s acting director, Dr. Jay Bhattacharya—who also oversees the National Institutes of Health—questioned the methodology in an April op-ed for *The Washington Post*.
“The CDC’s hesitation is puzzling, especially when the study aligns with previous findings that demonstrate the value of vaccination in preventing serious illness,” said Dr. Hotez. “Blocking it seems to contradict the goal of promoting public health through transparency.”
Dr. Bhattacharya argued that the study’s test-negative design may not account for all variables, such as prior infections or the effects of earlier vaccines. However, the authors acknowledged that the methodology has its limitations. For instance, they noted that some patients might have been hospitalized for reasons unrelated to COVID-19, and incomplete vaccine records could skew results. Additionally, low numbers of vaccinations and hospitalizations in certain groups constrained the analysis’s scope.
HHS Spokesperson Defends CDC’s Review Process
A Health and Human Services (HHS) spokesperson, Emily Hillard, told ABC News that the CDC’s decision to withhold the study was part of its commitment to rigorous scientific review. “When questions arise about methodology, we address them directly,” Hillard stated. “Responsible science requires careful review. Taking time to ensure analyses are methodologically sound and clearly communicated is always preferable to risking error.”
The statement emphasized that the CDC does not base conclusions on preconceived outcomes but evaluates evidence using strict standards. “We assess the weight of data through robust methods, communicate uncertainties, and subject our findings to scientific scrutiny before sharing them with the public,” Hillard added. This approach, while thorough, has drawn criticism for delaying critical information that could inform vaccination decisions.
Public Health Experts Praise the Methodology’s Utility
Despite its flaws, the test-negative design remains a valuable tool for measuring vaccine effectiveness, particularly when large healthcare databases are unavailable. Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, defended the approach. “We’ve been using test-negative design for years to try and answer questions like this,” he said. “When people, like in the administration, say it’s flawed or it gives results that aren’t reliable, they should specifically say why.”
Offit highlighted that the study’s methodology is consistent with prior work, ensuring comparability in findings. “The CDC’s block on this report may not fully reflect the evidence, but it’s important to recognize that no single approach is perfect,” he added. “The key is to use these methods to inform public health decisions rather than hinder them.”
The study’s publication comes amid a broader discussion about the CDC’s role in disseminating scientific research. While the agency’s cautious approach is seen as a safeguard against misinformation, critics argue that withholding data can create confusion and erode public trust. The findings, though not definitive, provide a compelling case for the updated vaccines as a critical component of pandemic response.
Context: Related Stories on Vaccine Research
Other recent developments have raised questions about the scientific integrity of vaccine-related reports. In April, the FDA withdrew publication of research findings on the safety of shingles and COVID-19 vaccines, further fueling debates about transparency in public health messaging. Meanwhile, the Trump administration has faced scrutiny for its handling of vaccine data, with some officials accused of prioritizing political narratives over scientific evidence.
These events underscore the importance of clear communication in vaccine research. As new variants emerge and booster campaigns continue, the public relies on timely and accurate information to make informed choices. The finalized study on the 2025-26 vaccine offers a step forward in this effort, even as it highlights the challenges of balancing thoroughness with urgency in scientific reporting.
With the study now available, healthcare professionals and policymakers can revisit its implications. While the CDC’s delay has sparked controversy, the data it ultimately released reinforces the vaccines’ effectiveness in mitigating severe illness. For many, the publication marks a significant victory in the ongoing fight to combat misinformation and ensure public health initiatives are grounded in sound science.
As the debate continues, the focus remains on how these findings will shape future vaccination strategies. The study’s authors hope their work will contribute to a more informed dialogue, emphasizing that while no research is without limitations, the benefits of vaccination are clear and supported by evidence.
